Telehealth platforms now generate prescriptions that reach compounding pharmacies, and the fee arrangements behind that volume are drawing direct enforcement attention. Paying a telehealth platform or marketing company a fee that rises with the number of prescriptions it sends, whether structured as a per-prescription payment or a percentage of reimbursement, is the compensation design the Anti-Kickback Statute's safe harbors were written to exclude, not protect. Compounding pharmacies that rely on telehealth lead generation face Anti-Kickback Statute exposure, False Claims Act liability for every claim the arrangement touches, and the same enforcement pattern that already cost one compounding pharmacy $21.36 million in a TRICARE settlement.
How Per-Prescription Fees Become Illegal Remuneration
The federal Anti-Kickback Statute makes it a felony to knowingly and willfully offer, pay, solicit, or receive anything of value to induce referrals of items or services reimbursable by a federal health care program, including TRICARE, Medicare, and Medicaid. A marketing fee tied to the number of prescriptions a telehealth platform generates for a compounding pharmacy, whether paid per prescription or as a percentage of the resulting reimbursement, functions as compensation for the referral itself rather than for a bona fide marketing service. Once the fee moves with prescription volume, the arrangement falls outside the statute's marketing and personal services safe harbors, and both the pharmacy and the platform face exposure.
The Compensation Rule Per-Prescription Fees Miss
The personal services and management contracts safe harbor at 42 CFR 1001.952(d) protects a marketing or services arrangement only if the compensation is set in advance, consistent with fair market value, and not determined in a manner that takes into account the volume or value of referrals or business generated between the parties. A flat monthly fee for advertising or platform access can satisfy that structure, but a fee that scales with prescriptions filled or dollars reimbursed cannot, because the compensation is doing exactly what the safe harbor was written to prevent. Pharmacies operating under 503A/503B compounding rules face this exposure with a telehealth platform, a call center, or an individual marketer alike.
OIG's Telemedicine Fraud Alert
On July 20, 2022, HHS's Office of Inspector General issued a Special Fraud Alert naming compensation tied to prescription or order volume as one of seven characteristics that mark a telemedicine arrangement as high risk. The alert, built on the enforcement experience of OIG and DOJ, including dozens of OIG fraud investigations, describes practitioners paid to order or prescribe items for patients they never meaningfully examined, through a telemedicine company that supplies a single class of products, such as prescription creams, rather than a full range of treatment options. OIG's alert states that compensation correlating with the volume of federally reimbursable prescriptions is intended to, and does, incentivize prescribing decisions that have nothing to do with medical necessity.
TRICARE's Compounding Fraud History
Compounding pharmacies paying marketers for prescriptions is not a new enforcement theory. DOJ reached a $21.36 million False Claims Act settlement in 2019 with compounding pharmacy Diabetic Care Rx, doing business as Patient Care America, its chief executive, its former vice president of operations, and the private equity firm that managed it, over a scheme that paid kickbacks to marketers to generate TRICARE-reimbursed prescriptions for pain creams, scar creams, and vitamins without regard to medical need. The marketers paid physicians to prescribe the compounded products through telemedicine encounters that did not include a proper patient examination. The structure now reappearing in telehealth-sourced compounding, a marketer paid out of the reimbursement stream it generates, is the same structure DOJ has already litigated once.
A marketing fee that rises and falls with the number of prescriptions it generates is the arrangement the Anti-Kickback Statute's safe harbors were written to exclude, not protect.
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel before signing a telehealth marketing agreement, and immediately upon receiving a subpoena, audit notice, investigative request, or other government inquiry touching a marketing arrangement already in place. Early legal intervention can protect the pharmacy's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance represents compounding pharmacies structuring and defending telehealth marketing relationships, including arrangements with platforms or marketing companies paid out of prescription volume. Related compounding compliance questions arise elsewhere in the firm's work, covered in Bulk Drug Substance Sourcing and the Section 503A Lists, cGMP Expectations for Outsourcing Facilities, and Cleanroom Certification and Recertification Timelines. If a telehealth marketing arrangement is already under review, contact Health Law Alliance for a free, confidential consultation on compounding pharmacy defense.
